Krystal Biotech Analysts Increase Their Forecasts Following Q4 Results

Krystal Biotech, Inc. (NASDAQ: KRYS) reported better-than-expected financial results for its fourth quarter on Monday.

Krystal Biotech posted quarterly earnings of 30 cents per share, compared to market expectations for a loss of 39 cents per share. The company’s quarterly sales came in at $42.14 million versus estimates of $28.61 million, according to data from Benzinga Pro.

“2023 was an inflection point for Krystal with the approval and launch of VYJUVEK, the first-ever FDA approved therapy for dystrophic epidermolysis bullosa and only medicine that delivers the corrective power of gene therapy in an easy-to-apply, redosable, topical gel formulation that can be administered at home,” said …

Full story available on Benzinga.com